helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2020-13-3-103-107helmholtzeyeinstitute-495Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWSРациональное лечение глаукомы у больных с сердечно-сосудистой патологиейSustainable treatment of glaucoma patients with cardiovascular diseasesЯкубоваЛ. В.YakubovaL. V.

Лия Вагизовна Якубова — кандидат медицинских наук, старший научный сотрудник отдела глаукомы.

Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062

Liya V. Yakubova — Cand. of Med.  Sci.,  senior  researcher, department of glaucoma.

14/19, Sadovaya Chernogryazskaya St., Moscow, 105062

yakoubova@yandex.ruКосакянС. М.KosakyanS. M.

Сбруи Мкртумовна Косакян — кандидат медицинских наук, врач-офтальмолог отдела глаукомы.

Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062

Srbui M. Kosakyan — Cand. of Med.  Sci., ophthalmologist, department of glaucoma.

14/19, Sadovaya Chernogryazskaya St., Moscow, 105062

ВасиленковаЛ. В.VasilenkovaL. V.

Любовь Васильевна Василенкова — кандидат медицинских наук, научный сотрудник отдела глаукомы.

Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062

Lubov V. Vasilenkova — Cand. of Med.  Sci.,  researcher, department of glaucoma.

14/19, Sadovaya Chernogryazskaya St., Moscow, 105062

ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава РоссииРоссияHelmholtz National Medical Research Center of Eye DiseasesRussian Federation202015092020133103107Copyright © Якубова Л.В., Косакян С.М., Василенкова Л.В., 20202020Якубова Л.В., Косакян С.М., Василенкова Л.В.Yakubova L.V., Kosakyan S.M., Vasilenkova L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/495

В связи с увеличением продолжительности жизни населения во всем мире ожидается рост числа больных глаукомой. В обзоре представлены данные о коморбидности и полипрагмазии у больных глаукомой пожилого и старческого возраста. Кроме того, для этих пациентов характерна полипатия:  каждый из них имеет в среднем 6,3 ± 0,6 сопутствующих соматических заболеваний. Примерно  каждый  пятый  пациент  с глаукомой получает  одновременно  системный  и местный  бета-адреноблокатор (БАБ). Применение больными глаукомой местных и системных БАБ создает потенциал для лекарственного взаимодействия, увеличения числа побочных эффектов  и более раннего наступления эффекта  тахифилаксии. Cелективность пероральных  и местных БАБ является  одним из факторов, способствующих прогнозированию их аддитивного  эффекта.  Приводятся данные о целесообразности назначения бримонидина  в качестве  препарата  первого выбора для больных глаукомой и глазной гипертензией, которым ранее были назначены системные БАБ.

As life expectancy  increases, the incidence  of glaucoma is expected to rise worldwide. The  review presents data on the comorbidity and polypharmacy of old and senile patients with glaucoma. Such patients also often have polypathia: on average, they have 6.3±0.6 concomitant somatic diseases. Approximately  one in five glaucoma patients receives both a systemic and local beta-blocker (ВВ).  Parallel use of local and systemic drugs in glaucoma patients is likely to cause drug interaction, increase side effects and contribute to an earlier onset of the tachyphylaxis. The selectivity of oral and local ВВ is one of the factors contributing to the prediction of their additive effect. The data on the expediency  of prescribing brimonidine  as the first-choice drug for glaucoma and hypertension  patients who were previously prescribed systemic ВВ are presented.

бета-адреноблокаторыкоморбидностьполипатияполипрагмазиясердечно-сосудистая патологияглаукомаbeta-blockerscomorbiditypolypathiapolypragmasiacardiovascular pathologyglaucomaReferencesKiseleva O.A., Kosakyan S.M., Yakubova L.V., Vasilenkova L.V. Interaction of antiglaucomatous drugs in patients with chronic concomitant diseases. Clinical ophthalmology. 2016; 16 (2): 16–9 (in Russian).Kiseleva O.A., Kosakyan S.M., Yakubova L.V., Vasilenkova L.V. Interaction of antiglaucomatous drugs in patients with chronic concomitant diseases. Clinical ophthalmology. 2016; 16 (2): 16–9 (in Russian).Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2002; 120 (10): 1268–79. doi: 10.1001/archopht.120.10.1268Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2002; 120 (10): 1268–79. doi: 10.1001/archopht.120.10.1268Neroev V.V., Kiseleva O.A., Bessmertny A.M. Main results of a multicenter study of epidemiological features of primary open angle glaucoma in the Russian Federation. Russian ophthalmological journal. 2013; 3: 4–7 (in Russian).Neroev V.V., Kiseleva O.A., Bessmertny A.M. Main results of a multicenter study of epidemiological features of primary open angle glaucoma in the Russian Federation. Russian ophthalmological journal. 2013; 3: 4–7 (in Russian).Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002; 120 (6): 701–13. doi: 10.1001/archopht.120.6.701Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002; 120 (6): 701–13. doi: 10.1001/archopht.120.6.701Kharkоv E.I., Davydov E.L., Shulmin A.V. Elderly patient and arterial hypertension: features of course and therapy (Message I). Siberian medical review. 2010; 3 (63): 3–8 (in Russian).Kharkоv E.I., Davydov E.L., Shulmin A.V. Elderly patient and arterial hypertension: features of course and therapy (Message I). Siberian medical review. 2010; 3 (63): 3–8 (in Russian).Onishchenko A.L., Kolbasko A.V., Zakharova A.V., Onishchenko E.G., Zhilina N.M. Ophthalmohypotensive effect of systemic use of beta-blockers in primary glaucoma and arterial hypertension. Vestnik oftal’mologii. 2017; 133 (2): 46–50 (in Russian). doi:10.17116/oftalma2017133246-50Onishchenko A.L., Kolbasko A.V., Zakharova A.V., Onishchenko E.G., Zhilina N.M. Ophthalmohypotensive effect of systemic use of beta-blockers in primary glaucoma and arterial hypertension. Vestnik oftal’mologii. 2017; 133 (2): 46–50 (in Russian). doi:10.17116/oftalma2017133246-50Makogon S.I., Makogon A.S. The features of comorbidity in primary openangle glaucoma patients in different age groups. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (6): 61–6 (in Russian).Makogon S.I., Makogon A.S. The features of comorbidity in primary openangle glaucoma patients in different age groups. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (6): 61–6 (in Russian).Stein J.D., Newman-Gasey P.A., Musch D.C., et al. Association between the use of glaucoma medications and mortality. Arch. Ophthalmol. 2010; 128 (2): 235–40. doi: 10.1001/archophthalmol.2009.378Stein J.D., Newman-Gasey P.A., Musch D.C., et al. Association between the use of glaucoma medications and mortality. Arch. Ophthalmol. 2010; 128 (2): 235–40. doi: 10.1001/archophthalmol.2009.378Masnoon N., Shakib S., Kalisch-Ellett L., et al. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017; 17 (1): 230. doi: 10.1186/s12877-017-0621-2Masnoon N., Shakib S., Kalisch-Ellett L., et al. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017; 17 (1): 230. doi: 10.1186/s12877-017-0621-2Diggory P., Franks W. Medical treatment of glaucoma — a reappraisal of the risks. Br. J. Ophthalmol. 1996; 80: 85–9. doi: 10.1136 / bjo.80.1.85Diggory P., Franks W. Medical treatment of glaucoma — a reappraisal of the risks. Br. J. Ophthalmol. 1996; 80: 85–9. doi: 10.1136/bjo.80.1.85Pereira K.G., Peres М.А., Iop D., et al. Polypharmacy among the elderly: a population-based study. Rev. Bras. Epidemiol. 2017; 20 (2): 335–44. doi: 10.1590/1980-5497201700020013Pereira K.G., Peres М.А., Iop D., et al. Polypharmacy among the elderly: a population-based study. Rev. Bras. Epidemiol. 2017; 20 (2): 335–44. doi: 10.1590/1980-5497201700020013Gottfredsdottir M.S., Allingham R.R., Shields M.B. Physicians’ guide to interactions between glaucoma and systemic medications. J. Glaucoma. 1997; 6: 377– 83.Gottfredsdottir M.S., Allingham R.R., Shields M.B. Physicians’ guide to interactions between glaucoma and systemic medications. J. Glaucoma. 1997; 6: 377– 83.Huber M., Kölzsch M., Stahlmann R., et al. Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma. Drugs Aging. 2013; 30 (1): 31–8. doi: 10.1007/s40266-012-0036-xHuber M., Kölzsch M., Stahlmann R., et al. Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma. Drugs Aging. 2013; 30 (1): 31–8. doi: 10.1007/s40266-012-0036-xGoldberg I., Adena M.A. Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clin. Exp. Ophthalmol. 2007; 35 (8): 700–5. doi.org/10.1111/j.1442-9071.2007.01573.xGoldberg I., Adena M.A. Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clin. Exp. Ophthalmol. 2007; 35 (8): 700–5. doi.org/10.1111/j.1442-9071.2007.01573.xCaughey G.E., Roughead E.E., Shakib S., et al. Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, crosssectional study of administrative claims data. Drugs Aging. 2011 Jul 1; 28 (7): 575–81. doi: 10.2165/11591090-000000000-00000Caughey G.E., Roughead E.E., Shakib S., et al. Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, crosssectional study of administrative claims data. Drugs Aging. 2011 Jul 1; 28 (7): 575–81. doi: 10.2165/11591090-000000000-00000Roughead E.E., Kalisch L.M., Pratt N.L., et al. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol. 2012; 19 (2): 74–82. doi: 10.3109/09286586.2011.638743Roughead E.E., Kalisch L.M., Pratt N.L., et al. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol. 2012; 19 (2): 74–82. doi: 10.3109/09286586.2011.638743Gurevich M.A. Chronic heart failure treatment in elderly patients. Russian Journal of Cardiology. 2008; (4): 93–100 (in Russian). https://doi.org/10.15829/1560-4071-2008-4-93-100Gurevich M.A. Chronic heart failure treatment in elderly patients. Russian Journal of Cardiology. 2008; (4): 93–100 (in Russian). https://doi.org/10.15829/1560-4071-2008-4-93-100Lee A.J., Wang J.J., Kifley A., et al. Open-angle glaucoma and cardiovascular mortality (The Blue Mountains Eye Study). Ophthalmology. 2006; 113: 1069–76. doi.org/10.3109/09286586.2011.638743Lee A.J., Wang J.J., Kifley A., et al. Open-angle glaucoma and cardiovascular mortality (The Blue Mountains Eye Study). Ophthalmology. 2006; 113: 1069–76. doi.org/10.3109/09286586.2011.638743Onishhenko A.L., Kolbasko A.V., Zhilina I.N., Isakov I.N., Vlasenko A.E. Life expectancy of patients with primary glaucoma, residents of a large industrial city of Siberia. Vestnik oftal'mologii. 2014; 2: 32–6 (in Russian).Onishhenko A.L., Kolbasko A.V., Zhilina I.N., Isakov I.N., Vlasenko A.E. Life expectancy of patients with primary glaucoma, residents of a large industrial city of Siberia. Vestnik oftal'mologii. 2014; 2: 32–6 (in Russian).Nedogoda S.V., Ledjaeva A.A., Chumachok E.G., et al. Beta-adrenolytic nebivolol nebivolol for the treatment of arterial hypertension in real clinical practice. Spravochnik poliklinicheskogo vracha. 2012; 1: 10–4 (in Russian).Nedogoda S.V., Ledjaeva A.A., Chumachok E.G., et al. Beta-adrenolytic nebivolol nebivolol for the treatment of arterial hypertension in real clinical practice. Spravochnik poliklinicheskogo vracha. 2012; 1: 10–4 (in Russian).Kiseleva O.A., Yakubova L.V., Bessmertny A.M. Beta-blockers in the treatment of glaucoma: history and prospects. Effective pharmacotherapy. Ophthalmology. 2018; 2: 4–17 (in Russian).Kiseleva O.A., Yakubova L.V., Bessmertny A.M. Beta-blockers in the treatment of glaucoma: history and prospects. Effective pharmacotherapy. Ophthalmology. 2018; 2: 4–17 (in Russian).Mäenpää J., Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin. Drug Saf.; 2016: 15 (11): 1549–61. doi.org/10.1080/14740338.2016.1225718Mäenpää J., Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin. Drug Saf.; 2016: 15 (11): 1549–61. doi.org/10.1080/14740338.2016.1225718Zimmerman T.J., Kooner K.S., Kandarakis A.S., et al. Improving the therapeutic index of topically applied ocular drugs. Arch. Ophthalmol. 1984; 102 (7): 601–4. doi: 10.1001/archopht.1984.01040030429017Zimmerman T.J., Kooner K.S., Kandarakis A.S., et al. Improving the therapeutic index of topically applied ocular drugs. Arch. Ophthalmol. 1984; 102 (7): 601–4. doi: 10.1001/archopht.1984.01040030429017Hoste A.M. Beta-Blockers. In: Shaarawy T.M., Sherwood M.B., Hitchings R.A., Crowston J.G., eds. Glaucoma — Medical Diagnosis & Therapy. London: Elsevier; 2014: 548–58.Hoste A.M. Beta-Blockers. In: Shaarawy T.M., Sherwood M.B., Hitchings R.A., Crowston J.G., eds. Glaucoma — Medical Diagnosis & Therapy. London: Elsevier; 2014: 548–58.De Moraes C.G., Cioffi G.A., Weinreb R.N., et al. New recommendations for the treatment of systemic hypertension and their potential implications for glaucoma management. Journal of Glaucoma. 2018; 27 (7): 567–71. doi.org/10.1097/IJG.0000000000000981De Moraes C.G., Cioffi G.A., Weinreb R.N., et al. New recommendations for the treatment of systemic hypertension and their potential implications for glaucoma management. Journal of Glaucoma. 2018; 27 (7): 567–71. doi.org/10.1097/IJG.0000000000000981Chauhan J.R., Mishra Y.C., Khilnani K. A clinical study of effect of oral atenolol on normal intraocular pressure and systemic blood pressure. Indian J. Ophthalmol. 1989; 37: 179–81. PMID: 2700474Chauhan J.R., Mishra Y.C., Khilnani K. A clinical study of effect of oral atenolol on normal intraocular pressure and systemic blood pressure. Indian J. Ophthalmol. 1989; 37: 179–81. PMID: 2700474Elliot M.J., Cullen P.M., Phillips C.I. Ocular hypotensive effect of atenolol (Tenormin, I.c.i.) A new beta-adrenergic blocker. Br. J. Ophthalmol. 1975; 59 (6): 296–300. doi: 10.1136/bjo.59.6.296Elliot M.J., Cullen P.M., Phillips C.I. Ocular hypotensive effect of atenolol (Tenormin, I.c.i.) A new beta-adrenergic blocker. Br. J. Ophthalmol. 1975; 59 (6): 296–300. doi: 10.1136/bjo.59.6.296Macdonald M.J., Cullen P.M., Phillips C.I. Atenolol versus propranolol. A comparison of ocular hypotensive effect of an oral dose. Br. J. Ophthalmol. 1976; 60 (11): 789–91. doi: 10.1136/bjo.60.11.789Macdonald M.J., Cullen P.M., Phillips C.I. Atenolol versus propranolol. A comparison of ocular hypotensive effect of an oral dose. Br. J. Ophthalmol. 1976; 60 (11): 789–91. doi: 10.1136/bjo.60.11.789Szumny D., Szeląg A. The influence of new beta-adrenolytics nebivolol and carvedilol on intraocular pressure and iris blood flow in rabbits. Graefe's Arch. Clin. and Exp. Ophthalmol. 2014; 252 (6): 917–23. doi: 10.1007/s00417-014-2623-5Szumny D., Szeląg A. The influence of new beta-adrenolytics nebivolol and carvedilol on intraocular pressure and iris blood flow in rabbits. Graefe's Arch. Clin. and Exp. Ophthalmol. 2014; 252 (6): 917–23. doi: 10.1007/s00417-014-2623-5Wettrell K., Pandolfi M. Effect on oral administration of various beta-blocking agents on the intraocular pressure in healthy volunteers. Exp. Eye Res. 1975; 21 (5): 451–6. doi: 10.1016/0014-4835(75)90126-8Wettrell K., Pandolfi M. Effect on oral administration of various beta-blocking agents on the intraocular pressure in healthy volunteers. Exp. Eye Res. 1975; 21 (5): 451–6. doi: 10.1016/0014-4835(75)90126-8Ohrström A., Pandolfi M. Long-term treatment of glaucoma with systemic propranolol. 1978. Am. J. Ophthalmol. 1978; 86: 340–4.Ohrström A., Pandolfi M. Long-term treatment of glaucoma with systemic propranolol. 1978. Am. J. Ophthalmol. 1978; 86: 340–4.Stenkula E., Wettrell K. A Dose-response study of oral atenolol administered once daily in patients with raised intra-ocular pressure. Graefe's Arch. Clin. Exp. Ophthalmol. 1982; 218: 96–8. doi: 10.1007/BF02153719Stenkula E., Wettrell K. A Dose-response study of oral atenolol administered once daily in patients with raised intra-ocular pressure. Graefe's Arch. Clin. Exp. Ophthalmol. 1982; 218: 96–8. doi: 10.1007/BF02153719Phillips C.I., Howitt G., Rowlands D.J. Propranolol as ocular hypotensive agent. Brit. J. Ophthal. 1967; 51: 222–6.Phillips C.I., Howitt G., Rowlands D.J. Propranolol as ocular hypotensive agent. Brit. J. Ophthal. 1967; 51: 222–6.Онищенко А.Л., Колбаско А.В., Сафронова М.А. и др. Изучение офтальмогипотензивной эффективности метопролола при парентеральном введении в эксперименте. Вестник офтальмологии. 2015; 131 (4): 79–82.Onishchenko A.L., Kolbasko A.V., Safronova M.A., et al. The study of the ophthalomohypotensive effectiveness of metoprolol when administered parenterally in the experiment. Vestnik oftal’mologii. 2015; 131 (4): 79–82 (in Russian).Batchelor E.D., O’Day D.M., Shand D.G., et al. Interaction of topical and oral timolol in glaucoma. Ophthalmology. 1979; 86: 60–5. doi: 10.1016/S0161-6420(79)35544-0Batchelor E.D., O’Day D.M., Shand D.G., et al. Interaction of topical and oral timolol in glaucoma. Ophthalmology. 1979; 86: 60–5. doi: 10.1016/S0161-6420(79)35544-0Blondeau P., Cote M., Tetrault L. Effect of timolol eye drops in subjects receiving systemic propanolol therapy. Can. J. Ophthalmol. 1983; 18: 18–21.Blondeau P., Cote M., Tetrault L. Effect of timolol eye drops in subjects receiving systemic propanolol therapy. Can. J. Ophthalmol. 1983; 18: 18–21.Williamson J., Young J.D.H., Atta H., et al. Comparative efficacy of orally and topically administered beta-blockers for chronic simple glaucoma. Br. J. Ophthalmol. 1985; 69: 41–5. doi: 10.1136/bjo.69.1.41Williamson J., Young J.D.H., Atta H., et al. Comparative efficacy of orally and topically administered beta-blockers for chronic simple glaucoma. Br. J. Ophthalmol. 1985; 69: 41–5. doi: 10.1136/bjo.69.1.41Gross F.J., Schuman J.S. Reduced ocular hypotensive effect of topical β-blockers in glaucoma patients receiving oral β-blockers. J. Glaucoma. 1992; 1 (3): 174–7.Gross F.J., Schuman J.S. Reduced ocular hypotensive effect of topical β-blockers in glaucoma patients receiving oral β-blockers. J. Glaucoma. 1992; 1 (3): 174–7.Schuman J.S. Effects of systemic -blocker therapy on the efficacy and safety of topical brimonidine and timolol. Ophthalmology. 2000 Jun; 107 (6): 1171–7. doi: 10.1016/s0161-6420(00)00081-6Schuman J.S. Effects of systemic -blocker therapy on the efficacy and safety of topical brimonidine and timolol. Ophthalmology. 2000 Jun; 107 (6): 1171–7. doi: 10.1016/s0161-6420(00)00081-6Schuman J.S., Horwitz B., Choplin N.T., et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter trial. Arch. Ophthalmol. 1997; 115: 847–52. doi: 10.1001/archopht.1997.01100160017002Schuman J.S., Horwitz B., Choplin N.T., et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter trial. Arch. Ophthalmol. 1997; 115: 847–52. doi: 10.1001/archopht.1997.01100160017002Le Blanc R P. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2 % and timolol 0.5 % given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology. 1998; 105: 1960–7. doi: 10.1016/s0161-6420(98)91048-xLe Blanc R P. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2 % and timolol 0.5 % given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology. 1998; 105: 1960–7. doi: 10.1016/s0161-6420(98)91048-xWeinreb R.N., Araie M., Susanna R., et al., eds. Medical treatment of glaucoma.Weinreb R.N., Araie M., Susanna R., et al., eds. Medical treatment of glaucoma.

The authors declare that there are no conflicts of interest present.